Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | TP53 |
Variant | P190L |
Impact List | missense |
Protein Effect | unknown |
Gene Variant Descriptions | TP53 P190L lies within the DNA-binding domain of the Tp53 protein (UniProt.org). P190L results in decreased transactivation of the Tp53 target gene, TLR3, but increased transactivation of TLR5 compared to wild-type Tp53 in cultured cells (PMID: 27533082), and therefore, its effect on Tp53 protein function is unknown. |
Associated Drug Resistance | |
Category Variants Paths |
TP53 mutant TP53 exon6 TP53 P190L |
Transcript | NM_000546.6 |
gDNA | chr17:g.7674962G>A |
cDNA | c.569C>T |
Protein | p.P190L |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001126116 | chr17:g.7673563G>A | c.569C>T | p.P190L | RefSeq | GRCh38/hg38 |
NM_001126113.3 | chr17:g.7674962G>A | c.569C>T | p.P190L | RefSeq | GRCh38/hg38 |
NM_001407264.1 | chr17:g.7674962G>A | c.569C>T | p.P190L | RefSeq | GRCh38/hg38 |
NM_001126114 | chr17:g.7674962G>A | c.569C>T | p.P190L | RefSeq | GRCh38/hg38 |
NM_001407262.1 | chr17:g.7674962G>A | c.569C>T | p.P190L | RefSeq | GRCh38/hg38 |
NM_001407270.1 | chr17:g.7674962G>A | c.569C>T | p.P190L | RefSeq | GRCh38/hg38 |
NM_000546.6 | chr17:g.7674962G>A | c.569C>T | p.P190L | RefSeq | GRCh38/hg38 |
NM_001126112.2 | chr17:g.7674962G>A | c.569C>T | p.P190L | RefSeq | GRCh38/hg38 |
NM_001126117 | chr17:g.7673563G>A | c.569C>T | p.P190L | RefSeq | GRCh38/hg38 |
NM_001126113.2 | chr17:g.7674962G>A | c.569C>T | p.P190L | RefSeq | GRCh38/hg38 |
NM_001126117.1 | chr17:g.7673563G>A | c.569C>T | p.P190L | RefSeq | GRCh38/hg38 |
NM_001126115.2 | chr17:g.7673563G>A | c.569C>T | p.P190L | RefSeq | GRCh38/hg38 |
NM_001407266.1 | chr17:g.7674962G>A | c.569C>T | p.P190L | RefSeq | GRCh38/hg38 |
NM_001126112 | chr17:g.7674962G>A | c.569C>T | p.P190L | RefSeq | GRCh38/hg38 |
NM_000546 | chr17:g.7674962G>A | c.569C>T | p.P190L | RefSeq | GRCh38/hg38 |
NM_001407268.1 | chr17:g.7674962G>A | c.569C>T | p.P190L | RefSeq | GRCh38/hg38 |
NM_001126114.2 | chr17:g.7674962G>A | c.569C>T | p.P190L | RefSeq | GRCh38/hg38 |
NM_001126117.2 | chr17:g.7673563G>A | c.569C>T | p.P190L | RefSeq | GRCh38/hg38 |
NM_001126114.3 | chr17:g.7674962G>A | c.569C>T | p.P190L | RefSeq | GRCh38/hg38 |
NM_001126113 | chr17:g.7674962G>A | c.569C>T | p.P190L | RefSeq | GRCh38/hg38 |
NM_001126116.1 | chr17:g.7673563G>A | c.569C>T | p.P190L | RefSeq | GRCh38/hg38 |
NM_001126115 | chr17:g.7673563G>A | c.569C>T | p.P190L | RefSeq | GRCh38/hg38 |
NM_001126116.2 | chr17:g.7673563G>A | c.569C>T | p.P190L | RefSeq | GRCh38/hg38 |
NM_001126112.3 | chr17:g.7674962G>A | c.569C>T | p.P190L | RefSeq | GRCh38/hg38 |
NM_000546.5 | chr17:g.7674962G>A | c.569C>T | p.P190L | RefSeq | GRCh38/hg38 |
NM_001126115.1 | chr17:g.7673563G>A | c.569C>T | p.P190L | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|